⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0130

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2022-08-01
Adverse events
8
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

severe assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 37); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-28 (study day 78); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 164); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-10-11 (study day 426); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-19 (study day 434); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-29 (study day 536); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-02-02 (study day 540); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-22 (study day 560); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.